These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 28341226)

  • 21. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
    J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Immune Heterogeneity Between Pulmonary Adenocarcinoma and Squamous Cell Carcinoma: A Comprehensive Analysis Based on lncRNA Model.
    Yan T; Ma G; Wang K; Liu W; Zhong W; Du J
    Front Immunol; 2021; 12():547333. PubMed ID: 34394068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling Differences in Molecular Mechanisms and Immunological Contrasts between Squamous Cell Carcinoma and Adenocarcinoma of the Cervix.
    Salarzaei M; van de Laar RLO; Ewing-Graham PC; Najjary S; van Esch E; van Beekhuizen HJ; Mustafa DAM
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
    Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T
    Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.
    Jang HJ; Lee HS; Ramos D; Park IK; Kang CH; Burt BM; Kim YT
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1598-1610.e3. PubMed ID: 31879171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
    Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
    Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer.
    Komaki R; Milas L; Ro JY; Fujii T; Perkins P; Allen P; Sikes CR; Mountain CF; Ordonez NG
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):787-96. PubMed ID: 9531362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes.
    Zhang YK; Zhu WY; He JY; Chen DD; Huang YY; Le HB; Liu XG
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1641-50. PubMed ID: 22618509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
    Sepesi B; Nelson DB; Mitchell KG; Gibbons DL; Heymach JV; Vaporciyan AA; Swisher SG; Roszik J
    Ann Thorac Surg; 2018 Jun; 105(6):1621-1626. PubMed ID: 29510096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Immune Subtypes and Landscape of Squamous Cell Carcinoma.
    Li B; Cui Y; Nambiar DK; Sunwoo JB; Li R
    Clin Cancer Res; 2019 Jun; 25(12):3528-3537. PubMed ID: 30833271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome analyses identify the genetic modification of lung cancer subtypes.
    Zhang Y; Wang DC; Shi L; Zhu B; Min Z; Jin J
    Semin Cancer Biol; 2017 Feb; 42():20-30. PubMed ID: 27845189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.